Citations

Clear

1446 citation(s) found for "Howard, F".

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202
Dignam, James J., Hamstra, Daniel A. , Lepor, Herbert , Grignon, David J. , Brereton, Harmar D., Zeitzer, Kenneth L. , Venkatesan, Varagur, Horwitz, Eric M. , Pisansky, Thomas M. , Currey, Adam D. , Rosenthal, Seth A. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | December 7, 2018 | Volume: 37 | Issue: 3 | Pages: 213-221

10.1200/jco.18.00154 | PMID 30526194 Get It

Background In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been evaluated in the context of radiotherapy and short-term androgen deprivation (AD), potential surrogates under long-term (24 month) AD, a proven therapy in high-risk localized disease, have not been investigated. Materials and Methods In the NRG/RTOG 9202 randomized trial (N = 1,520) of short-term AD (4 months) versus long-term AD (LTAD; 28 months), the time interval free of biochemical failure (IBF) was evaluated in relation to clinical end points of prostate cancer–specific survival (PCSS) and overall survival (OS). Survival modeling and landmark analysis methods were applied to evaluate LTAD benefit on IBF and clinical end points, association between IBF and clinical end points, and the mediating effect of IBF on LTAD clinical end point benefits. Results LTAD was superior to short-term AD for both biochemical failure (BF) and the clinical end points. Men remaining free of BF for 3 years had relative risk reductions of 39% for OS and 73% for PCSS. Accounting for 3-year IBF status reduced the LTAD OS benefit from 12% (hazard ratio [HR], 0.88; 95% CI, 0.79 to 0.98) to 6% (HR, 0.94; 95% CI, 0.83 to 1.07). For PCSS, the LTAD benefit was reduced from 30% (HR, 0.70; 95% CI, 0.52 to 0.82) to 6% (HR, 0.94; 95% CI, 0.72 to 1.22). Among men with BF, by 3 years, 50% of subsequent deaths were attributed to prostate cancer, compared with 19% among men free of BF through 3 years. Conclusion The IBF satisfied surrogacy criteria and identified the benefit of LTAD on disease-specific survival and OS. The IBF may serve as a valid end point in clinical trials and may also aid in risk monitoring after initial treatment.
Multimodal imaging in familial FTLD: phenoconversion and planning for the future
Rosen, Howard J. , Boeve, Bradley F.

Mayo Clinic

Brain | December 5, 2018 | Volume: 142 | Issue: 1 | Pages: 8-11

10.1093/brain/awy314 | PMID 30596906 Get It

Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus
Buckley, Melissa A., Woods, Nicholas T. , Mendoza-Fandiño, Gustavo, Lawrenson, Kate , Hazelett, Dennis J. , Najafabadi, Hamed S. , Gjyshi, Anxhela, Carvalho, Renato S. , Lyra, Paulo C. , Shen, Howard C., Yang, Ally , Earp, Madalene A. , Yoder, Sean J., Chenevix‐Trench, Georgia , Ramus, Susan J. , Phelan, Catherine M., Coetzee, Gerhard A., Hughes, Timothy R. , Sellers, Thomas A. , Goode, Ellen L. , Gayther, Simon A. , Monteiro, Álvaro N.A. , Lu, Karen H. , Goodman, Marc T. , Lissowska, Jolanta , Jakubowska, Anna , Dörk, Thilo , Matsuo, Keitaro , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Ekici, Arif B. , Chen, Y. Ann , Eccles, Diana , Teo, Soo‐Hwang , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Jensen, Allan , Brooks‐Wilson, Angela , Sieh, Weiva , Dansonka‐Mieszkowska, Agnieszka , Liang, Dong , Woo, Yin Ling , McNeish, Iain A. , Lambrechts, Diether , Lawrenson, Kate , Hazelett, Dennis J , Najafabadi, Hamed S , Coetzee, Simon G , Ramus, Susan J , Noushmehr, Houtan , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Lissowska, Jolanta , Brooks-Wilson, Angela R , Matsuo, Keitaro , Jakubowska, Anna , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Chenevix-Trench, Georgia , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Yoder, Sean , Risch, Harvey A. , Noushmehr, Houtan , Pharoah, Paul D.P. , Morais Lyra, Paulo Cilas

Mayo Clinic

Cancer Research | November 28, 2018 | Volume: 79 | Issue: 3 | Pages: 467-481

10.1158/0008-5472.can-17-3864 | PMID 30487138 Get It

Abstract Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and assess underlying biological mechanisms at chromosome 9p22.2, the first and most statistically significant associated locus for ovarian cancer susceptibility. Three transcriptional regulatory elements with allele-specific effects and a scaffold/matrix attachment region were characterized and, through physical DNA interactions, BNC2 was established as the most likely target gene. We determined the consensus binding sequence for BNC2 in vitro, verified its enrichment in BNC2 ChIP-seq regions, and validated a set of its downstream target genes. Fine-mapping by dense regional genotyping in over 15,000 ovarian cancer cases and 30,000 controls identified SNPs in the scaffold/matrix attachment region as among the most likely causal variants. This study reveals a comprehensive regulatory landscape at 9p22.2 and proposes a likely mechanism of susceptibility to ovarian cancer. Significance: Mapping the 9p22.2 ovarian cancer risk locus identifies BNC2 as an ovarian cancer risk gene. See related commentary by Choi and Brown, p. 439
CENTRALIZED COGNITIVE ASSESSMENT IN A MULTICENTER TRIAL OF TREATMENT MODES FOR ASYMPTOMATIC CAROTID ARTERY DISEASE
Wadley, Virginia G. , Lal, Brajesh K. , Brott, Thomas G. , Lazar, Ronald M. , Howard, Virginia J. , Knopman, David S. , Meschia, James F. , Howard, George

Mayo Clinic

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 702-702

10.1093/geroni/igy023.2607 Get It

Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia
Vairo, Filippo Pinto e , Ferrer, Alejandro , King, Rebecca L. , Howard, Matthew T., Viswanatha, David S., Klee, Eric W. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Cathcart-Rake, Elizabeth , Patnaik, Mrinal , Vairo, Filippo , Ferrer, Alejandro

Mayo Clinic

Leukemia & Lymphoma | November 8, 2018 | Volume: 60 | Issue: 5 | Pages: 1337-1339

10.1080/10428194.2018.1522443 | PMID 30407884 Get It

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
Fisher, Barbara, Macdonald, David , Chakravarti, Arnab , Lesser, Glenn J. , Fox, Sherry, Coons, Stephen W., Rogers, Leland , Werner‐Wasik, Maria, Doyle, Thomas J. , Bahary, Jean-Paul , Fiveash, John B. , Bovi, Joseph , Howard, Steven , Yu, Michael , D’Souza, David , Roach, Mack , Kwok, Young , Wahl, Daniel , Stasser, John, Won, Minhee , Zhang, Peixin, Fox, Sherry, Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi11-vi11

10.1093/neuonc/noy148.039 Get It

Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients
Woolley, Susan , Goetz, Ray, Factor‐Litvak, Pam , Murphy, Jennifer , Hupf, Jonathan , Lomen‐Hoerth, Catherine , Andrews, Howard , Heitzman, Daragh, Bedlack, Richard , Katz, Jonathan, Barohn, Richard J., Sorenson, Eric J. , Oskarsson, Björn , Filho, Americo Fernandes, Kasarskis, Edward J. , Mozaffar, Tahseen , Nations, Sharon , Swenson, Andrea , Koczon-Jaremko, Agnes, Christodoulou, Georgia , Mitsumoto, Hiroshi , Garofalo, Diana C. , Sorenson, Eric, Oskarsson, Björn , Bedlack, Richard S , Christodoulou, Georgia

Mayo Clinic

Behavioural Neurology | October 31, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/5969137 | PMID 30515252 Get It

Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS). Methods. We analyzed data from 294 ALS participants, 134 of whom were studied serially. Change over time was evaluated controlling for age, sex, symptom duration, education, race, and ethnicity. Using multiple regression, we evaluated associations among decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores, forced vital capacity (FVC), and cognitive/behavioral changes. Change in cognitive/behavioral subgroups was assessed using one-way analyses of covariance. Results. Participants with follow-up data had fewer baseline behavior problems compared to patients without follow-up data. We found significant worsening of behavior (ALS Cognitive Behavioral Screen (ALS CBS) behavioral scale, p<0.001; Frontal Behavioral Inventory-ALS (FBI-ALS) disinhibition subscale, p=0.044). Item analysis suggested change in frustration tolerance, insight, mental rigidity, and interests (p<0.05). Changes in ALSFRS-R correlated with the ALS CBS. Worsening disinhibition (FBI-ALS) did not correlate with ALSFRS-R, FVC, or disease duration. Conclusion. We did not detect cognitive change. Behavioral change was detected, and increased disinhibition was found among patients with abnormal baseline behavioral scores. Disinhibition changes did not correlate with disease duration or progression. Baseline behavioral problems were associated with advanced, rapidly progressive disease and study attrition.